Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perspective TherapeuticsCATX -0.33%31 Debt-to-Equity is 0.01 as of Mar. 2026, which is at its 10-year median of 0.01. GuruFocus rates CATX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Perspective Therapeutics ranks better than 99.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Perspective Therapeutics's Debt-to-Equity or its related term are showing as below:
CATX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.19
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Perspective Therapeutics was 0.19. The lowest was 0.01. And the median was 0.01.
CATX's Debt-to-Equity is ranked better than 99.86% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CATX: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Perspective Therapeutics Debt-to-Equity Related Terms
Perspective Therapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Perspective Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perspective Therapeutics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (CATX) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Perspective Therapeutics and its competitors. This is near median its historical median of 0.01. Over the past decade, Perspective Therapeutics' Debt-to-Equity has ranged from 0.01 to 0.19. According to the industry distribution chart, Perspective Therapeutics ranks #1 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Perspective Therapeutics' Debt-to-Equity too high?
Perspective Therapeutics' current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.19. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Perspective Therapeutics' value of 0.01 is 95.7% below this industry median. Based on the distribution chart, Perspective Therapeutics ranks #1 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Debt-to-Equity compare to CV and LAB?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #1 out of 706 companies for Debt-to-Equity. This places Perspective Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Perspective Therapeutics' value of 0.01 is 95.7% below this benchmark. Historically, Perspective Therapeutics' own Debt-to-Equity has ranged from 0.01 to 0.19 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 0.23, Perspective Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perspective Therapeutics's current Debt-to-Equity of 0.01 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 95.7% below the Medical Devices & Instruments industry median of 0.23. Perspective Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score
Get the complete analysis for CATX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CATX has been successfully added to your 
